Trial · NCT03327571
Outcomes72
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 72
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Group 2, RRHL: Progression Free Survival (PFS) | From initiation of first treatment until first documentation of relapse/PD/until date of death (or date when participant was last alive), whichever occurred first (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. | months | MEDIAN |
| SECONDARY | Group 1, cHL: Number of Participants Based on Clinical Staging According to Ann Arbor Staging at Diagnosis | Day 1 at cHL diagnosis | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Number of Participants Based on Clinical Staging According to Ann Arbor Staging at Diagnosis | Day 1 at RRHL diagnosis | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Number of Participants Based on Clinical Staging According to Ann Arbor Staging at Relapse After First Relapse or Refractory Diagnosis | At second, third, fourth, and fifth relapse (up to 9 years 10 months) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 1, cHL: Number of Participants Based on Each International Prognostic Score (IPS) Category | Day 1 at cHL diagnosis | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 1, cHL: Number of Participants With B Symptoms at Diagnosis | Day 1 at cHL diagnosis | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Number of Participants With B Symptoms at Diagnosis | Day 1 at RRHL diagnosis | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Number of Participants Categorized Based on Prior Therapies for Hodgkin Lymphoma (HL) at Each Line of Treatment | Day 1 at RRHL diagnosis | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Median Number of Previous Treatment Regimens (Chemotherapies) Received | Day 1 at RRHL diagnosis | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | previous treatment regimen | MEDIAN |
| SECONDARY | Group 1, cHL: Number of Participants Categorized Based on Frontline Treatment Regimens | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 1, cHL: Median Number of Treatment Cycles Associated With Each Frontline Treatment Regimen | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. Here number analyzed n are the participants who were evaluable for the outcome measure at given categories. | cycles | MEDIAN |
| SECONDARY | Group 1, cHL: Number of Participants Who Received Treatments for HL After Completion of Frontline Therapy (Before Relapse) | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 1, cHL: Number of Participants Based on Radiotherapy (RT) Type and Site When Received at Frontline | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 1, cHL: Number of Participants Categorized Based on RT Treatment Given as Pre-planned Frontline Treatment and RT Treatment Given for Residual Fluorodeoxyglucose (FDG)-Avid Disease | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for cHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Percentage of Participants Categorized Based on ASCT Eligibility Assessment | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. Here number analyzed n are the participants who were evaluable for the outcome measure at given categories. | percentage of participants | NUMBER |
| SECONDARY | Group 2, RRHL: Median Number of Treatment Cycles Associated With Relapse/ Refractory Treatment Regimen for ASCT | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. . Here overall number of participants analyzed are those who were evaluable for this outcome measure. Here number analyzed n are the participants who were evaluable for the outcome measure at given categories. | cycles | MEDIAN |
| SECONDARY | Group 2, RRHL: Number of Non-ASCT Participants Categorized Based on Reasons for Not Undergoing ASCT Despite Being ASCT Eligible | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including common participants. Here overall number of participants analyzed are those who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Number of Non-ASCT Participants Based on Reasons for ASCT Ineligibility | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. Here number analyzed n are the participants who were evaluable for the outcome measure at given categories. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Number of Non-ASCT Participants Categorized Based on Treatment Regimens Received at Each Line of Treatment | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. Here number analyzed n are the participants who were evaluable for the outcome measure at given categories. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Group 2, RRHL: Percentage of Non-ASCT Participants for Whom Treatment is Palliative | From initial diagnosis until the date of death (or the date when the participant was last known to be alive) (observed retrospectively from 2010 until date of data collection [up to 9 years 10 months]) | The FAS included all participants who were eligible for RRHL group including the common participants in both the groups. Here overall number of participants analyzed are those who were evaluable for this outcome measure. Here number analyzed n are the participants who were evaluable for the outcome measure at given categories. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03327571/outcomes